Purpose PET/CT has a major role in lymphoma imaging, but glycolytic activity in inflammatory processes can reduce specificity. In this study we evaluated restaging PET/CT findings in patients with non-Hodgkin lymphoma (NHL) and fat necrosis. Methods We identified 16 patients from 8,819 restaging FDG PET/CT scans with suspicion of or biopsy-proven fat necrosis on PET/CT.
Introduction
18 F-FDG PET/CT has become an integral component of patient management in lymphoma [1] [2] [3] . Compared to conventional imaging, advantages include high tumour to background contrast, high reproducibility [4] and the ability to assess response before anatomical changes or exclude active disease in patients with residual masses. Although it is very sensitive, FDG uptake is not specific for malignant processes. There are several nonlymphomatous physiological and pathological causes of FDG uptake [5] [6] [7] [8] , and a thorough knowledge of these processes and their imaging features are important to limit unnecessary interventions. Some of the physiological causes include metabolic activity associated with brown adipose tissue, muscle, bowel and female genital organs [5] . Similarly, reactive lymph node changes, rebound thymic hyperplasia, postradiotherapy pneumonitis and inflammatory diseases also show increased FDG uptake [5] [6] [7] . Diffuse increases in bone marrow and splenic uptake can also be seen after administration of haematopoietic growth factors, whilst focal bony involvement may be attributable to bony remodelling rather than active disease [9, 10] . We discuss a series of patients with non-Hodgkin lymphoma (NHL) and high focal FDG uptake following treatment associated with presumed or proven fat necrosis that could present a pitfall in interpretation of PET/CT scans.
Materials and methods
We retrospectively analysed the cases of patients with NHL who were referred for FDG PET/CT after treatment and in whom "fat necrosis" was suspected on imaging, or its presence was proven histopathologically. Patients were identified by searching PET/CT reports from January 2006 to October 2012 performed for lymphoma restaging containing the words "fat necrosis" or "mesenteric panniculitis" or similar-sounding words. Haematologists were also surveyed for known cases of histopathologically proven fat necrosis to identify patients who were not identified prospectively on PET/CT. Details of patient characteristics, diagnosis, treatment, PET findings and follow-up are presented in Table 1 . This research was approved by the Centre for Cancer Imaging, Peter MacCallum Cancer Centre, and constituted a clinical audit not requiring ethics committee approval according to institutional guidelines.
PET/CT imaging was performed on a combined PET/CT scanner, either a Discovery 690 or STE (GE Medical Systems, Milwaukee, WI) or a Biograph 64 (Siemens Medical Solutions USA, Malvern, PA) scanner. The dose of FDG was weightadjusted using 3.6 MBq/kg for the Discovery 690 and Biograph 64, and 4.2 MBq/kg for the Discovery STE; the actual mean administered dose was 256 MBq, range 144-314 MBq. Mean uptake time was 68 min (range 60-81 min). Low-dose contemporaneous CT was performed in all patients without intravenous or oral administration of contrast agent. The baseline and index PET/CT and available contrast-enhanced CT studies were reviewed to identify any patterns associated with fat necrosis, including measurement of standardized uptake value (SUVmax) and CT density (Hounsfield units).
Histopathological review of the positive specimens was performed by a single histopathologist (S.L.). Immunohistochemistry was performed using anti-GLUT-1 monoclonal antibody (Thermo Scientific; clone SPM498) and routine staining protocols on a Ventana platform (Roche, Basel, Switzerland).
Results
During the study period, 8,819 FDG PET/CT scans were performed in 3,342 patients for lymphoma restaging. Fat necrosis was identified in 16 patients (seven women, nine men) with a median age of 59 years (range 26-71 years). Of these patients, 2 had well-controlled diabetes mellitus, but none had lymphoma-related symptoms at the time of the scan. Thirteen had histologically aggressive NHL, while 3 had follicular lymphoma. Five patients had received radiotherapy to the site at which the PET abnormality was detected. The median time between the last treatment and the PET scan was 8 weeks (range 4-40 weeks). All these studies showed a complete metabolic response at all other previous sites of disease except for the solitary abnormal focus. Biopsy was subsequently performed in 8 patients and confirmed fat necrosis (Fig. 1 ).
PET/CT findings
The foci of fat necrosis were most commonly seen in the mesentery (14 patients), and also in the breast and mediastinal fat (1 patient each). Prior to initiation of treatment for the NHL, bulky disease (>10 cm lesion diameter) was seen in five patients while mesenteric vessel encasement was noted in six. The average maximum diameter of the residual metabolically active lesion was 20 mm (range 15-28 mm) with a mean SUVmax of 6.4 (range 3.8-13.2). The lesions had smooth or ill-defined borders on the contemporaneous CT images with surrounding fat stranding in all patients (Fig. 2c) . The mean CT density of the lesions was −12.5 HU, which was lower than the density measured along the psoas muscle (46.1 HU) for comparison as a soft tissue density (p<0.05). In three patients the lesions demonstrated an area of central fat density surrounded by a soft tissue density giving a "doughnut" appearance ( Fig. 3 ). All the patients with the abnormal foci in the mesentery showed features of mesenteric stranding and nodules on their pretreatment imaging.
Follow-up
Follow-up of a minimum of 6 months was available in 12 patients. Of these 12 patients, 2 had surgical excision of the suspected lesions and confirmation on subsequent histological examination. No residual lesions were seen on postsurgery PET/CT scans in these two patients. A further six patients had biopsy confirmation, with the follow-up PET/CT scan demonstrating complete resolution in three (at 9, 10 and 12 months) and partial resolution in three (starting as early as 1 month, but persisting up to a year). At the time of this report, surveillance was continuing in four patients beyond 6 months without documented recurrence.
Histopathology
Specimens from five of eight patients with histologically confirmed fat necrosis were available for central review. Histology demonstrated typical features of fat necrosis with macrophage infiltration, fibrosis and sparse mature chronic inflammatory cells. There was no evidence of recurrent lymphoma in any of the samples. Some specimens showed discrete areas of fibrosis. GLUT-1 immunohistochemistry showed a prominent perinecrotic staining pattern but no staining in viable organizing tissue or the necrotic area (Fig 4) .
Discussion
FDG PET/CT has become a standard of care for restaging in patients with aggressive NHL. It has a very high negative predictive value and a moderate positive predictive value in detection of residual disease [1] . Several physiological and show an FDG-avid ill-defined lesion in the mesentery with complete metabolic response elsewhere. Note mesenteric stranding on the CT images both before and after treatment inflammatory nonlymphomatous conditions also cause FDG uptake, reducing its specificity and necessitating skill in interpretation. Understanding this has become more relevant in recent years as consensus criteria for reporting are being established [11] .
Fat necrosis mimicking residual disease has been described in isolated case reports [12, 13] . This was a rare finding in this series, occurring in 0.2 % of total scans or 0.5 % of patients scanned for restaging lymphoma. It is probable that other cases were not identified, so the true incidence of fat necrosis is likely to be higher. All identified patients had biopsy-proven NHL and were free of lymphoma-related symptoms at the time of imaging. In most of the patients the focus of fat necrosis was identified within a year of the last treatment (chemotherapy or radiotherapy). The characteristic "doughnut sign" of fat necrosis was only seen in three patients [14] . Given that the intensity of uptake was in the range typical for residual/recurrent lymphoma, the presence of moderate to intense FDG avidity might lead an inexperienced reader to report it as disease recurrence. We have identified some radiological features which assist in determining that fat necrosis is likely. Though the lesions appear similar to nodal lesions, they have a lower density than soft tissue which can be confirmed by measurement of the CT density. Another notable feature is that all the patients showed complete response at all other sites of disease. Interestingly, in nine patients (56 %), the area of fat necrosis was not located at sites of baseline disease. To the best of our knowledge this is the first description of FDG PET findings in histologically confirmed supradiaphragmatic fat necrosis (one in the neck and another in the breast in our series) in the literature.
All the patients with mesenteric fat necrosis showed features of mesenteric stranding and nodules on the baseline study. These findings might be considered to be due to mesenteric panniculitis (MP) but the lack of FDG avidity at baseline might suggest an alternative aetiology such as venous and lymphatic congestion. The radiological findings in MP include a "misty" appearance of the mesentery with a hyperdense stripe of variable thickness surrounding the area of mesenteric changes (or mass) separating it from normal adjacent mesentery [15, 16] . Nodular changes may also be noted in MP. The density of these areas was lower than that of soft tissue but more than that of uninvolved fat. Daskalogiannaki et al. [15] reported features of MP in 0.6 % of patients undergoing CT, with 69 % having an associated malignancy such as lymphoma, ovarian cancer or colonic cancer. However, Canyigit et al. [17] found that MP occurs more frequently in association with benign disorders. In a retrospective series of 19 patients with MP who had undergone FDG PET/CT, Zissin et al. [18] found that all patients with FDG-avid nodules had tumoral involvement whilst benign MP did not show FDG uptake. In our series, mesenteric stranding was noted in 11 patients while non-FDG-avid nodular changes on the baseline study were seen in 7. Finally, Joerger et al. [19] reported that CT features of MP were present in 9 % of patients with NHL.
In most patients in our cohort who were observed, the abnormal FDG uptake had either completely or partially resolved on follow-up scans, confirming the nonprogressive and self-limiting nature of the process. The metabolic activity, however, can persist for as long as 12 months. One of the limitations of our study was that although the patients did not have recurrent disease or progression of the lesions, the period of follow-up was relatively short in some of the patients. The aetiology of fat necrosis is often unclear, although causes such as infection, trauma and ischaemia have been suggested. In our series, only one patient had surgical debulking, which could potentially have led to fat necrosis from intraoperative trauma. Mesenteric ischaemia may have contributed to the development of fat necrosis in our series, with encasement of mesenteric vessels and/or bulky mesenteric nodal involvement seen in eight patients. Ischaemia from posttreatment radiation fibrosis involving the mesenteric vessels may also have been a contributory factor, although only a minority of the patients received radiation (five patients).
Conclusion
In conclusion, fat necrosis is a potential cause of nonlymphomatous uptake on FDG PET/CT scans in patients with NHL after treatment. The occurrence of fat necrosis appears to be related to features of MP on the pretreatment PET/CT scan and could be a result of trauma, ischaemia or vascular compromise from either the disease or its treatment. Although rare, fat necrosis should be included in the differential diagnosis of the cause of a solitary FDG-avid lesion after therapy in NHL. Understanding the clinical setting and imaging features described should assist in recognition of this potential pitfall and avoid unnecessary interventions or inappropriate treatment. 
